As of September 15, 2023, if an individual had invested $100 in Biogen (BIIB) stock 15 years ago, they would now possess a remarkable sum of $555.61. This impressive growth is based on the current price of BIIB at $255.78. Biogen has consistently surpassed market expectations over the past 15 years, achieving an annualized outperformance of 3.36% and an average annual return of 12.4%. Furthermore, the total return for BIIB over the past ten years, ending on June 29, 2023, amounts to an impressive 30.22%.
Updated on: 15/09/2023
Debt to equity ratio: Buy
Price to earnings ratio: Strong Buy
Price to book ratio: Strong Buy
DCF: Strong Buy
2:00 PM (UTC)
Date:15 September, 2023
|Analyst / firm||Rating|
Biogen Inc. Stock Analysis and Market Overview for September 15, 2023
On September 15, 2023, Biogen Inc. (BIIB) had a previous close of $256.26. The stock opened at $256.21 and had a day’s range of $255.03 to $257.51. The volume for the day was 17,815 shares. The market cap for Biogen Inc. is $37.5 billion.
Biogen Inc. saw a positive growth of 100.92% in the previous year. However, the earnings growth for this year has declined by 12.67%. Looking ahead, the projected earnings growth for the next five years is expected to be 4.11%. The revenue growth for the previous year was -9.32%.
Biogen Inc. has a P/E ratio of 13.9. The price/sales ratio is 4.29, while the price/book ratio is 2.79.
On September 15, 2023, Moderna Inc. (MRNA) saw an increase of $1.56, or 1.38%, while Illumina Inc. (ILMN) experienced a decrease of $4.63, or 3.08%. Biomarin Pharmaceutical Inc. (BMRN) had a positive change of $1.30, or 1.48%.
The next reporting date for Biogen Inc. is scheduled for October 24, 2023. The earnings per share forecast for this quarter is $4.07. In the previous year, Biogen Inc. generated an annual revenue of $9.4 billion and a profit of $3.0 billion. The net profit margin for the company is 32.30%.
Biogen Inc. operates in the health technology sector and is specifically involved in the biotechnology industry. The company is headquartered in Cambridge, Massachusetts.
BIIB Stock Shows Promising Performance and Analysts Predict Growth in 2023
BIIB Stock Shows Positive Performance with Analysts Predicting Growth
Biogen Inc’s stock (BIIB) showed promising performance on September 15, 2023, with analysts forecasting a potential increase in its value. According to data sourced from CNN Money, 27 analysts have provided 12-month price forecasts for BIIB, with a median target of $330.00.
The consensus among 36 polled investment analysts is to buy stock in Biogen Inc, indicating a consistent belief in the company’s potential for growth.
Biogen Inc is a leading biotechnology company known for its groundbreaking research and development of therapies for neurological and neurodegenerative diseases.
The positive outlook for BIIB stock can be attributed to several factors. Firstly, Biogen has a robust pipeline of potential treatments in various stages of development. These include promising candidates for diseases like Parkinson’s, spinal muscular atrophy, and amyotrophic lateral sclerosis.
Additionally, Biogen has demonstrated its ability to successfully commercialize its products. The company’s flagship drug, Tecfidera, has been a major revenue driver, generating billions of dollars in sales annually.
Furthermore, Biogen has been actively pursuing strategic partnerships and acquisitions to enhance its product portfolio and expand its market reach.
Investors should also take note of Biogen’s upcoming earnings report, scheduled for October 24. The current quarter’s earnings per share stand at $4.07, indicating a healthy financial performance.
In conclusion, Biogen Inc’s stock performance on September 15, 2023, suggests positive growth potential. With a robust pipeline of potential treatments, successful commercialization of existing products, strategic partnerships, and upcoming earnings report, Biogen Inc appears well-positioned for future success.